Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Other Working Capital Changes (2016 - 2024)

Historic Other Working Capital Changes for Protalix BioTherapeutics (PLX) over the last 15 years, with Q2 2024 value amounting to $1.7 million.

  • Protalix BioTherapeutics' Other Working Capital Changes rose 11404.58% to $1.7 million in Q2 2024 from the same period last year, while for Jun 2024 it was $12.7 million, marking a year-over-year increase of 17173.94%. This contributed to the annual value of -$13.2 million for FY2023, which is 8399.89% down from last year.
  • Protalix BioTherapeutics' Other Working Capital Changes amounted to $1.7 million in Q2 2024, which was up 11404.58% from $11.0 million recorded in Q1 2024.
  • Protalix BioTherapeutics' Other Working Capital Changes' 5-year high stood at $16.0 million during Q2 2021, with a 5-year trough of -$11.8 million in Q2 2023.
  • For the 5-year period, Protalix BioTherapeutics' Other Working Capital Changes averaged around -$1.4 million, with its median value being -$2.6 million (2022).
  • Its Other Working Capital Changes has fluctuated over the past 5 years, first plummeted by 825555.56% in 2020, then soared by 89531.7% in 2024.
  • Over the past 5 years, Protalix BioTherapeutics' Other Working Capital Changes (Quarter) stood at -$11.1 million in 2020, then soared by 93.58% to -$715000.0 in 2021, then tumbled by 125.87% to -$1.6 million in 2022, then plummeted by 630.03% to -$11.8 million in 2023, then soared by 114.05% to $1.7 million in 2024.
  • Its last three reported values are $1.7 million in Q2 2024, $11.0 million for Q1 2024, and -$11.8 million during Q2 2023.